DK1005460T3 - Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthase - Google Patents
Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthaseInfo
- Publication number
- DK1005460T3 DK1005460T3 DK98944529T DK98944529T DK1005460T3 DK 1005460 T3 DK1005460 T3 DK 1005460T3 DK 98944529 T DK98944529 T DK 98944529T DK 98944529 T DK98944529 T DK 98944529T DK 1005460 T3 DK1005460 T3 DK 1005460T3
- Authority
- DK
- Denmark
- Prior art keywords
- cox
- inhibitors
- cyclooxygenase
- biosynthesis
- synthase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 4
- 108010037464 Cyclooxygenase 1 Proteins 0.000 abstract 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91866197A | 1997-08-22 | 1997-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1005460T3 true DK1005460T3 (da) | 2006-07-10 |
Family
ID=25440748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98944529T DK1005460T3 (da) | 1997-08-22 | 1998-08-20 | Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthase |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1005460B1 (da) |
| JP (1) | JP2002511887A (da) |
| AT (1) | ATE319691T1 (da) |
| CA (1) | CA2294548A1 (da) |
| CY (1) | CY1105027T1 (da) |
| DE (1) | DE69833774T2 (da) |
| DK (1) | DK1005460T3 (da) |
| ES (1) | ES2260846T3 (da) |
| PT (1) | PT1005460E (da) |
| WO (1) | WO1999010332A1 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| CA2307111C (en) | 1997-11-19 | 2009-06-30 | Kowa Co., Ltd. | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| TR200101765T2 (tr) * | 1998-10-27 | 2002-02-21 | Abbott Laboratories | Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri |
| JP2000247959A (ja) | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−３−オン誘導体及びこれを含有する医薬 |
| US6649629B2 (en) | 1999-12-23 | 2003-11-18 | Nitromed, Inc. | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
| US7211577B2 (en) | 2003-03-18 | 2007-05-01 | Kowa Co., Ltd. | Water-soluble phenylpyridazine derivative and medicine containing the same |
| PL1745791T3 (pl) | 2003-05-07 | 2013-11-29 | Osteologix As | Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu |
| EP1650195A4 (en) * | 2003-07-30 | 2008-09-17 | Kowa Co | METHOD FOR INHIBITING OSTEOPONTIN PRODUCTION |
| DE102004010207A1 (de) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| ES2524922T3 (es) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| CA3209491A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3934436A1 (de) * | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
-
1998
- 1998-08-20 PT PT98944529T patent/PT1005460E/pt unknown
- 1998-08-20 WO PCT/US1998/017618 patent/WO1999010332A1/en active IP Right Grant
- 1998-08-20 DE DE69833774T patent/DE69833774T2/de not_active Expired - Fee Related
- 1998-08-20 CA CA002294548A patent/CA2294548A1/en not_active Abandoned
- 1998-08-20 AT AT98944529T patent/ATE319691T1/de not_active IP Right Cessation
- 1998-08-20 ES ES98944529T patent/ES2260846T3/es not_active Expired - Lifetime
- 1998-08-20 JP JP51459699A patent/JP2002511887A/ja not_active Ceased
- 1998-08-20 EP EP98944529A patent/EP1005460B1/en not_active Expired - Lifetime
- 1998-08-20 DK DK98944529T patent/DK1005460T3/da active
-
2006
- 2006-05-09 CY CY20061100599T patent/CY1105027T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2294548A1 (en) | 1999-03-04 |
| DE69833774T2 (de) | 2007-04-26 |
| EP1005460A1 (en) | 2000-06-07 |
| ATE319691T1 (de) | 2006-03-15 |
| WO1999010332A1 (en) | 1999-03-04 |
| EP1005460B1 (en) | 2006-03-08 |
| JP2002511887A (ja) | 2002-04-16 |
| PT1005460E (pt) | 2006-07-31 |
| DE69833774D1 (en) | 2006-05-04 |
| CY1105027T1 (el) | 2010-03-03 |
| ES2260846T3 (es) | 2006-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1124804T3 (da) | Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase | |
| CA2299300A1 (en) | Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors | |
| DK1005460T3 (da) | Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthase | |
| Chan et al. | Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles | |
| Carabaza et al. | Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs | |
| Esser et al. | Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2 | |
| Raz | Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)?: in vitro versus in vivo results and the relevance for the prevention and treatment of cancer | |
| Liu et al. | Involvement of cyclo‐oxygenase‐1‐mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries | |
| BRPI0011172B8 (pt) | derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2 | |
| Chen et al. | Syntheses and biological activities of sulfoximine-based acyclic triaryl olefins | |
| WO2003093793A3 (en) | Binary or polynary targeting and uses thereof | |
| Morrison et al. | Mechanism of enhanced renal prostaglandin biosynthesis in ureter obstruction. Role of de novo protein synthesis. | |
| Petrovic et al. | Using N, N, N’, N’-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro | |
| Devaux et al. | Lipopolysaccharide-induced increase of prostaglandin E2 is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase | |
| Ratheesh et al. | Protective effects of isolated polyphenolic and alkaloid fractions of Ruta graveolens L. on acute and chronic models of inflammation | |
| FR2897864B1 (fr) | Composition d'amorcage et applications | |
| Biava | Introduction to COX inhibitors | |
| WO2004047772A3 (en) | Catalytic antioxidants and methods of use | |
| TR200000478T2 (tr) | Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar. | |
| Engelhardt et al. | Biological activity of the main metabolites of meloxicam. | |
| McCulloch et al. | Fluorescent Mechanism‐Based Probe for Aerobic Flavin‐Dependent Enzyme Activity | |
| Tavares | The effects of meloxicam, indomethacin or NS‐398 on eicosanoid synthesis by fresh human gastric mucosa | |
| Rowland et al. | Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic,[3-(3, 4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2-(5H)-furanone], in multiple preclinical species | |
| De Godoy et al. | Arachidonic acid metabolites follow the preferential course of cyclooxygenase pathway for the basal tone in the internal anal sphincter | |
| Khanapure et al. | 3-[4-(Methylsulfonyl) phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: Synthesis and biological evaluation |